FLT1

(redirected from VEGFR-1)

FLT1

A gene on chromosome 13q12 that encodes a member of the vascular endothelial growth factor receptor (VEGFR) family of receptor tyrosine kinases (RTKs), which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment and a tyrosine kinase (TK) domain within the cytoplasmic domain. FLT1 binds to VEGFR-A, VEGFR-B and placental growth factor, plays an important role in angiogenesis and is expressed in vascular endothelial cells, placental trophoblast cells and monocytes.
Mentioned in ?
References in periodicals archive ?
Circulating levels of free and total VEGF-A, soluble VEGFR-1 and VEGFR-2 and angiogenin during ovarian stimulation in non-human primates and women.
VEGFR-1 reduces cell proliferation and organizes capillary branching and networking, while VEGFR-2 is responsible for vascular cell proliferation and promotes vascular branching and maintenance of endothelial cells (14).
Although some new reports indicated the association between preterm labour and angiogenic factors (sEng, PlGF, PIGF/sEng and VEGFR-1) (15), we selected a control group with the same gestational age as the percreta group to achieve gestational age similarity between the groups.
The pathway encompasses six ligands (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF) with three cognate receptors (VEGFR-1, VEGFR-2, and VEGFR-3) [18, 19].
VEGF-A binds to two high-affinity receptor tyrosine kinases, VEGFR-1 (FMS-like tyrosine kinase-1 or Flt-1) and VEGFR-2 (kinase insert domain-receptor or KDR), which are abundant in vascular endothelial cells.
used the experimental mouse model to show the role of VEGF-B in the development of arthritis and found that the mouse was protected against synovial inflammation and the formation of joint destruction by inhibiting the binding of VEGF-B to the receptor (VeGfR-1).
Nien et al., "A role of the anti-angiogenic factors VEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome)," The Journal of Maternal-Fetal and Neonatal Medicine, vol.
However, when the diabetic mice were treated with the blocking antibodies specialized for VEGF-B receptor, the neutralization of VEGFR-1 completely abolished the increased expression of NGF and GDNF stimulated by SA injection.
Its targets include MET, AXL and VEGFR-1, -2 and -3, proteins that promote tumor angiogenesis (blood vessel growth), growth, invasiveness and metastasis.
CABOMETYX is the tablet formulation of cabozantinib and its targets include MET, AXL and VEGFR-1, -2 and -3.
Expression of the VEGF receptors VEGFR-1 (Flt-a) and VEGFR-2 (KDR/Flk-1) in Tenon fibroblasts was increased and fibroblast proliferation was stimulated following in vitro delivery of VEGF.